Register or Sign in to Save this opportunity, or Send an Inquiry.
Abiraterone Acetate Tablets (250mg)
ELC GROUP S.r.o. Czech Republic flag Czech Republic
Abstract ID:
Abiraterone Acetate is the generic form of branded drug ZYTIGA® used along with prednisone to treat men with castration-resistant prostate cancer (cancer that is resistant to medical or surgical treatments) that has spread to other parts of the
Send an Inquiry

Abiraterone acetate is indicated for use in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer. It has received FDA approval on 28 April 2011, EMA approval on 23 September 2011, MHRA approval on 5 September 2011 and TGA approval on 1 March 2012 for this indication. Zytiga has been one of Johnson & Johnson’s best new drug launches with global sales totalling $2.2 billion in 2015.

Type of Business Relationship Sought
Out Licensing
Last Updated Nov 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833